Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M. Palumbo A, et al. Among authors: pregno p. Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1. Blood. 2010. PMID: 19965659 Free article. Clinical Trial.
Combined differentiating therapy for myelodysplastic syndromes: a phase II study.
Ferrero D, Bruno B, Pregno P, Stefani S, Larizza E, Ciravegna G, Luraschi A, Vietti-Ramus G, Schinco P, Bazzan M, Gallo E, Pileri A. Ferrero D, et al. Among authors: pregno p. Leuk Res. 1996 Oct;20(10):867-76. doi: 10.1016/0145-2126(95)00156-5. Leuk Res. 1996. PMID: 8960111 Clinical Trial.
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A. Tarella C, et al. Among authors: pregno p. Cancer. 2003 Jun 1;97(11):2748-59. doi: 10.1002/cncr.11414. Cancer. 2003. PMID: 12767087 Free article.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: pregno p. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Palumbo A, et al. Among authors: pregno p. Blood. 2007 Apr 1;109(7):2767-72. doi: 10.1182/blood-2006-08-042275. Blood. 2007. PMID: 17148584 Free article. Clinical Trial.
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A. Ladetto M, et al. Among authors: pregno p. J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308672 Clinical Trial.
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A. Benevolo G, et al. Among authors: pregno p. Cancer. 2011 May 1;117(9):1884-90. doi: 10.1002/cncr.25743. Epub 2010 Nov 18. Cancer. 2011. PMID: 21509765 Free article. Clinical Trial.
95 results